10 Apr Out-of-Pocket Costs for Insulin Are a Problem
Out-of-Pocket Costs for Insulin Are a Problem.
Litigants in Case Disagree on Who Is at Fault
After a year in court, the leading insulin manufacturers and the attorneys suing them agree: Some people with
diabetes pay a lot of money out of pocket for the hormone that keeps them alive.
They disagree, however, on whether laws have been broken and who should be blamed. The insulin
manufacturers argue the problem of rising prices is beyond the court’s ability to solve.
Soon judges overseeing the 14-month-old suit will decide whether they agree. With a stay lifted in the case, the
insulin companies have filed a scathing motion to dismiss the racketeering claims lodged against them.
But in doing so, the drugmakers admit that consumers’ sticker shock is real. It’s just not the manufacturers’
fault, they argue. And it’s definitely not a crime.
“Defendants acknowledge that pharmaceutical p ricing is an important issue, especially given how recent trends
in the design of insurance benefits have affected certain patients’ out of pocket costs,” states the joint
motion filed on March 9, 2018, by attorneys for Novo Nordisk, Sanofi, and Eli Lilly.